ABBV vs PG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Procter & Gamble Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
AbbVie Inc. · Healthcare
$197.69
+11.0% upside to fair value
Grade C
High Quality
VS
The Procter & Gamble Company · Consumer Defensive
$143.45
+13.8% upside to fair value
Grade B
High Quality
QuantHub Verdict
PG has more upside to fair value
(+13.8%).
PG trades at a lower forward P/E
(20.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PG |
| Current Price |
$197.69 |
$143.45 |
| Fair Value Estimate |
$219.51 |
$163.27 |
| Upside to Fair Value |
+11.0%
|
+13.8%
|
| Market Cap |
$349.7B |
$334.0B |
| Forward P/E |
83.3x
|
20.8x
|
| EV / EBITDA |
23.4x
|
15.4x
|
| Price / Sales |
5.7x
|
3.9x
|
| Price / FCF |
18.7x
|
22.2x
|
| Revenue Growth YoY |
+10.0%
|
+7.4%
|
| Gross Margin |
70.2%
|
50.3%
|
| Operating Margin |
26.7%
|
23.2%
|
| Return on Equity |
-361.6%
|
31.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
4.5%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
The Procter & Gamble Company is a leading consumer defensive firm specializing in household and personal products with a diversified portfolio across fabric and home care, baby and family care, beauty, health care, and grooming segments. The business quality is high, supported by durable brands, strong margins with a 50.3% gross margin and 19.2% net margin, and consistent earnings growth evidence…
Accumulation Zones
| Metric |
ABBV |
PG |
| Zone Low |
$164.63 |
$122.45 |
| Zone High |
$186.58 |
$138.78 |
| In Buy Zone? |
No
|
No
|